Eli Lilly and Company

Amunix Operating Inc.

John Michael Beals

Andrew Ihor Korytko

David Bruce Baldwin

Gregory Alan Lazar

Jonathan Wesley Day

Craig Duane Dickinson

Shun Li

Volker Schellenberger

Christopher Carl Frye

Wolfgang Glaesner

Radmila Micanovic

Lianshan Zhang

Beth Ann Strifler

Radhakrishnan Rathnachalam

Monica Rixman Swinney

Bryant McLaughlin

Jing Shang

Eric Dwayne Hawkins

Anthony Shane Ransdell

Shantanu Virendra Sule

Vikram Paritosh Sinha

Melvin Jay Prince

Gordon Butler Cutler, Jr

Ryan John Hansen

Brandon Doyle

Shahriar Shirani

Gordon Butler Cutler

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

Fusion proteins

The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol

Fusion proteins and methods of use

The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.

Blood glucose lowering compound

The present invention relates to an improved method for treating diabetes wherein the improvement comprises administering a PEGylated insulin compound to a patient having moderate to severe chronic kidney disease using an effective amount of the compound.

Treatment for comorbid diabetes with chronic kidney disease

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.

PEGylated insulin lispro compounds

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Muteins of fibroblast growth factor 21

Growing community of inventors

Indianapolis, IN, United States of America

John Michael Beals